Table 2 |
||||||
|
Mean IADL and PSMS scores for all patients and the sub-sample who had NARTIQ scores at baseline (week 0) and after 26, 52 and 78 weeks of cholinesterase inhibitor treatment; higher scores indicate greater dependency |
||||||
|
Assessment |
N All patients |
Mean |
Standard deviation |
N Patients with NARTIQ |
Mean |
Standard deviation |
|
|
||||||
|
IADL(0) |
551 |
15.8 |
6.5 |
294 |
14.7 |
6.2 |
|
PSMS(0) |
548 |
7.9 |
3.1 |
292 |
7.5 |
2.9 |
|
IADL(26) |
238 |
17.3 |
5.9 |
146 |
16.9 |
5.9 |
|
PSMS(26) |
237 |
8.5 |
3.0 |
146 |
8.3 |
2.8 |
|
IADL(52) |
75 |
16.5 |
7.2 |
59 |
16.7 |
7.1 |
|
PSMS(52) |
74 |
8.1 |
3.5 |
58 |
8.1 |
3.4 |
|
IADL(78) |
46 |
18.0 |
6.1 |
39 |
18.0 |
6.5 |
|
PSMS(78) |
46 |
8.5 |
2.7 |
39 |
8.4 |
2.8 |
|
|
||||||
|
Starr and Lonie BMC Psychiatry 2008 8:27 doi:10.1186/1471-244X-8-27 |
||||||
